Valrubicin – 500 µg

Brand:
Cayman
CAS:
56124-62-0
Storage:
-20
UN-No:
- 2811 / 6.1

Valrubicin is a semisynthetic anthracycline antitumor antibiotic and derivative of doxorubicin (Item No. 15007).{40337} It inhibits the growth of human bladder tumor cell lines with LD50 values ranging from 0.05 to 11.2 μM.{40339} Valrubicin is more active against cells in the plateau growth phase than in the log growth phase (LD70s = 2.5 and 12.1 μM, respectively for CUB-2 cells). Valrubicin (40 mg/kg) increases survival in mice with murine P388 and L1210 leukemias.{40337} Topical administration of valrubicin (0.01 g/ml) reduces epidermal thickness and normalizes epidermal morphology in a mouse psoriasis xenograft transplantation model.{40338} Formulations containing valrubicin have been used in the treatment of bladder cancer.  

 

Available on backorder

SKU: 22964 - 500 µg Category:

Description

A semisynthetic anthracycline antitumor antibiotic; inhibits the growth of human bladder tumor cell lines (LD50s = 0.05-11.2 μM); more active against cells in the plateau growth phase than in the log growth phase (LD70s = 2.5 and 12.1 μM, respectively for CUB-2 cells); increases survival in mice with murine P388 and L1210 leukemias; reduces epidermal thickness and normalizes epidermal morphology in a mouse psoriasis xenograft transplantation model


Formal name: pentanoic acid, 2-[(2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(2,2,2-trifluoroacetyl)amino]-α-L-lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-2-oxoethyl ester

Synonyms:  NSC 246131|N-Trifluoroacetyladriamycin-14-valerate

Molecular weight: 723.6

CAS: 56124-62-0

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals||Research Area|Cancer||Research Area|Immunology & Inflammation|Autoimmunity